Navigation Links
Evista Not A Cure For Heart Disease

Evista is the market name of the drug raloxifene HCl is manufactured by drug maker Eli Lilly & Co. a study was conducted which showed that Evista// , a drug used to treat osteoporosis in women, did not prevent heart attacks. The study analyzed 10,000 women in 26 countries for a period of seven years. It was studied whether if this drug given daily for the study period would lower the risks of heart attack and breast cancer in postmenopausal women who either had heart disease or were at high risk for heart attack.

Raloxifene HCl is mainly used to treat and prevent osteoporosis in postmenopausal women. But since this study proved that the drug did not prevent heart attacks the company wanted to reinforce for physicians that Evista should not be prescribed for cardioprotection. Lilly Chief Medical Officer Alan Breier said in a statement that they have gathered new data on Evista's potential to reduce the risk of invasive breast cancer in postmenopausal women. It plans to submit the details of its study to the Food and Drug Administration for review. But further analysis would be needed and precautionary measures to be taken before announcing the use of the drug with respect to breast cancer.
'"/>




Page: 1

Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Epileptic Seizures Can Be Due to Heart Problem
3. Bypass Heart Surgery Performed Without General Anesthesia
4. New CPR Guidelines issued by Heart Association
5. White Cells Count Can Predict Heart Attack Death Risk
6. Vitamins-The answer to Heart Disease?
7. Fight Heart disease and Pain with Meditation
8. Heart disease in the newborn is related to maternal malnutrition
9. New drug to treat Heart Attack and damaged tissue
10. Heart disease threat starts early in life for Diabetics
11. Mechanical Heart
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/24/2016)... ... May 24, 2016 , ... The Dream Builders Project, a 501(c)3 nonprofit organization ... Eunime Orphanage in Tijuana, Mexico on Saturday, May 21st. The volunteers took the children ... , More than 15 volunteers traveled from Los Angeles to Tijuana, Mexico for ...
(Date:5/24/2016)... PA (PRWEB) , ... May 24, 2016 , ... ... manufacturer of safety signs and safety labels , has been ... “Understanding Symbols: Laser Labels.” , The eiXtra e-newsletter provides electroindustry professionals with manufacturer, ...
(Date:5/24/2016)... ... May 24, 2016 , ... Global Lyme Alliance (GLA), ... announced that it has named Scott Santarella as its new CEO. , ... Foundation (ALCF) in San Francisco, where he successfully helped to grow the organization ...
(Date:5/24/2016)... ... 24, 2016 , ... After graduating from Cornell, author Joshua Alexander ... on medication, living on Social Security disability and staying in a group home. In ... It!” (published by Balboa Press), Alexander shares how he was finally able to heal ...
(Date:5/24/2016)... ... , ... PhysicianOne Urgent Care, advocators in helping their patients lead the healthiest ... being bitten this spring. , The official tick season kicks off in May ... known for attaching themselves to their prey while they feed off their blood. Like ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... LAWRENCEVILLE, N.J. , May 24, 2016 /PRNewswire/ ... an oncology drug development company, today provided an ... Ib dose escalating clinical trial combining GEN-1, the ... for the treatment of newly-diagnosed patients with advanced ... by interval debulking surgery.  GEN-1 is an IL-12 ...
(Date:5/24/2016)... HONG KONG , May 24, 2016 ... , the world , s ... and AV fistula intervention   OrbusNeich, a ... solutions, has expanded its portfolio to include products to ... balloons are the company,s first entry devices for lower ...
(Date:5/24/2016)... , May 24, 2016 ... ™ , la première endoprothèse à ... destinés à l,intervention portant sur les membres ... OrbusNeich, entreprise mondiale spécialisée dans ... changer la vie, a élargi son portefeuille ...
Breaking Medicine Technology: